1. Home
  2. FRBA vs MYGN Comparison

FRBA vs MYGN Comparison

Compare FRBA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bank

FRBA

First Bank

HOLD

Current Price

$16.46

Market Cap

397.1M

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.72

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRBA
MYGN
Founded
2007
1991
Country
United States
United States
Employees
320
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.1M
444.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FRBA
MYGN
Price
$16.46
$4.72
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$18.50
$7.64
AVG Volume (30 Days)
58.8K
1.6M
Earning Date
04-27-2026
05-05-2026
Dividend Yield
2.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$14.68
$6.89
Revenue Next Year
$6.08
$5.35
P/E Ratio
$9.71
N/A
Revenue Growth
N/A
2.33
52 Week Low
$12.74
$3.76
52 Week High
$18.11
$8.59

Technical Indicators

Market Signals
Indicator
FRBA
MYGN
Relative Strength Index (RSI) 63.56 48.27
Support Level $16.08 $4.23
Resistance Level $17.41 $5.69
Average True Range (ATR) 0.39 0.28
MACD 0.13 0.03
Stochastic Oscillator 93.69 55.89

Price Performance

Historical Comparison
FRBA
MYGN

About FRBA First Bank

First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: